<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04548843</url>
  </required_header>
  <id_info>
    <org_study_id>PLC-PMD-01-IL</org_study_id>
    <nct_id>NCT04548843</nct_id>
  </id_info>
  <brief_title>A First in Human Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion</brief_title>
  <official_title>A First in Human Phase I, Open Label Dose-escalation Study to Evaluate the Safety of Infusion of MNV-BM-PLC (Autologous CD34+ Cells Enriched With Placenta Derived Allogeneic Mitochondria) in Patients With Primary Mitochondrial Diseases Associated With Mitochondrial DNA Mutation or Deletion</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Minovia Therapeutics Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Minovia Therapeutics Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study objectives are to evaluate the safety of a single intravenous (IV) infusion of&#xD;
      autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria in participant&#xD;
      with primary mitochondrial disease associated with mitochondrial DNA mutations or deletions.&#xD;
&#xD;
      6 participants aged from 4 to 18 years old on the day of screening visit with primary&#xD;
      mitochondrial disease associated with mitochondrial DNA mutations or deletions will be&#xD;
      enrolled.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MNV-BM-PLC is a personalized cell therapy based on autologous patient-derived Hematopoietic&#xD;
      stem/progenitor cells (HSPCs) enriched with mitochondria isolated from healthy placenta&#xD;
      obtained from donors during C-section. Healthy mitochondria are employed, ex-vivo, to enrich&#xD;
      the patient's CD34+ peripheral blood cells, followed by infusion of the mitochondrial&#xD;
      enriched cells back to the patient. This therapeutic process of mitochondrial augmentation&#xD;
      provides the patient with healthy mitochondria carrying non-mutated/deleted mtDNA that can&#xD;
      supplement mitochondrial functionality in the patient's cells.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 2022</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">March 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>The study will involve two sequential cohorts:&#xD;
Cohort 1: 3 patients will be administrated with Dose 1 The dosing interval between patients will be at minimum 2 weeks. Two (2) weeks after the 3rd patient has received MNV-BM-PLC, the Data safety monitoring board (DSMB) will convene to review accumulated safety data. The DSMB will make a recommendation whether to proceed with the 4th patient administration.&#xD;
Cohort 2: 3 patients will be administrated with Dose 2 The dosing interval between patients will be at minimum 2 weeks.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with Treatment-related adverse events as assessed by CTCAE v5.0 following MNV-BM-PLC</measure>
    <time_frame>1 month</time_frame>
    <description>Severity will graded according to CTCAE, Version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of hemoglobin level</measure>
    <time_frame>1 month</time_frame>
    <description>Change from baseline in hematological parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of absolute neutrophil count</measure>
    <time_frame>1 month</time_frame>
    <description>Change from baseline in hematological parameter</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Measurement of platelet count</measure>
    <time_frame>1 month</time_frame>
    <description>Change from baseline in hematological parameter</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with Treatment-related adverse events as assessed by CTCAE v5.0 following MNV-BM-PLC</measure>
    <time_frame>2 years</time_frame>
    <description>Severity will graded according to CTCAE, Version 5.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of hemoglobin level</measure>
    <time_frame>2 years</time_frame>
    <description>Change from baseline in hematological parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of absolute neutrophil count</measure>
    <time_frame>2 years</time_frame>
    <description>Change from baseline in hematological parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Measurement of platelet count</measure>
    <time_frame>2 years</time_frame>
    <description>Change from baseline in hematological parameter</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IPMDS (International Pediatric Mitochondrial Disease Scale)</measure>
    <time_frame>2 years</time_frame>
    <description>To compare the change in International Pediatric Mitochondrial Disease Scale (IPMDS) score during a follow up period of 3, 6 12 and 24 months post treatment. IPMDS total score ranges from 0 to 243. The score is expressed as the percentage of items which were feasible to perform. The lower the score is, the higher the child's function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Performance Score</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilization or improvement in performance score (Lansky score (for patients younger than 15 years) or Karnofsky (for patients older than 15) score relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PEDI: Pediatric Evaluation of Disability Inventory</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilization or improvement in PEDI score relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>6-minute walk test</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilization or improvement in 6-minute walk test relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>30 Second chair stand</measure>
    <time_frame>2 years</time_frame>
    <description>Stabilization or improvement in 30 Second chair stand relative to baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization events</measure>
    <time_frame>1 year</time_frame>
    <description>Reduction in number, cause and duration of hospitalization events relative to 12 months before IP treatment</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">6</enrollment>
  <condition>Primary Mitochondrial Diseases</condition>
  <arm_group>
    <arm_group_label>Cohort 1 &amp; Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 patients will be administrated with Dose 1 (0.88 mitochondria unit (mU) citrate synthase (CS) activity per million cells).&#xD;
3 patients will be administrated with Dose 2 (4.4mU mitochondria unit (mU) citrate synthase (CS) activity per million cells).</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Bone Marrow mobilization</intervention_name>
    <description>During four days before the apheresis, Neupogen (G-CSF) at a dose of 10 microgram per kilogram will be administered subcutaneously in the morning (days -6 to -3 of cell therapy). In addition, Mozobil (Plerixafor) at a dose of 0.24 milligram per kilogram will be administered subcutaneously approximately 4 hours before apheresis initiation.&#xD;
A fifth dose of Neupogen (G-CSF) will be administered just prior to the apheresis</description>
    <arm_group_label>Cohort 1 &amp; Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Apheresis</intervention_name>
    <description>Apheresis will be performed two days prior to MNV-BM-PLC infusion. During this procedure, patient's peripheral blood will be collected by apheresis</description>
    <arm_group_label>Cohort 1 &amp; Cohort 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>MNV-BM-PLC infusion</intervention_name>
    <description>The MNV-BM-PLC (autologous CD34+ cells enriched with placenta-derived allogeneic mitochondria) infusion will be performed by standard IV procedure.&#xD;
The dosing interval between patients will be at minimum 2 weeks.</description>
    <arm_group_label>Cohort 1 &amp; Cohort 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Molecular diagnosis of primary mitochondrial disease&#xD;
&#xD;
          -  Age between 4 years and up to 18 years, with a minimum body weight of 20 (+/-1)&#xD;
             kilogram on the day of screening visit.&#xD;
&#xD;
          -  Performance score: Karnofsky â‰¥40 (or equivalent in children younger than 16 years old.&#xD;
&#xD;
          -  Patients or Patient's parents or legal guardian (where applicable) has a good&#xD;
             understanding of the study and nature of the procedure and is willing and able to&#xD;
             provide written informed consent prior to participation in any study-related&#xD;
             procedures.&#xD;
&#xD;
          -  Medical ability to undergo the study procedures safely, as determined by the&#xD;
             investigator.&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Positive test for pathogenic agents .&#xD;
&#xD;
          -  Inability to undergo leukapheresis, as determined by the investigator.&#xD;
&#xD;
          -  Chronic severe infection or any other disease or condition that may risk the patient&#xD;
             or interfere with the ability to interpret the study results.&#xD;
&#xD;
          -  Known history of malignancy.&#xD;
&#xD;
          -  Patient has been treated within the last one year prior to IP treatment with a&#xD;
             different cell therapy.&#xD;
&#xD;
          -  Patient has participated in another interventional clinical study and/or received&#xD;
             other experimental medication outside of a clinical study within 1 month prior the day&#xD;
             of Investigation product (IP) treatment visit.&#xD;
&#xD;
          -  A pregnant or lactating woman or a woman who plans to become pregnant during the&#xD;
             study. In addition, any woman of childbearing potential (not sterile or&#xD;
             postmenopausal), who is unwilling to adhere to the use highly effective contraception&#xD;
             method for the duration of the study&#xD;
&#xD;
          -  In the opinion of the Investigator, the patient is unsuitable for participating in the&#xD;
             study due to safety concerns.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Eyal Shoshani</last_name>
    <phone>972544758318</phone>
    <email>eyal@minoviatx.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Lea Bensoussan</last_name>
    <phone>972-58-610-1291</phone>
    <email>lea@minoviatx.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sheba Medical Center - Tel Ashomer</name>
      <address>
        <city>Ramat Gan</city>
        <country>Israel</country>
      </address>
    </facility>
    <contact>
      <last_name>Elad Jacobi, MD</last_name>
      <phone>972-3-5303037</phone>
      <email>elad.jacoby@sheba.gov.il</email>
    </contact>
    <contact_backup>
      <last_name>Diana Chigalayev</last_name>
      <phone>972-3-5307145</phone>
      <email>diana.chigalayev@sheba.gov.il</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>September 8, 2020</study_first_submitted>
  <study_first_submitted_qc>September 8, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 16, 2020</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 31, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mitochondrial DNA Mutation or Deletion</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitochondrial Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

